United States securities and exchange commission logo





                               August 10, 2022

       Amanda Fenster
       Partner
       Weil, Gotshal & Manges LLP
       767 Fifth Avenue
       New York, New York 10153

                                                        Re: Covetrus, Inc.
                                                            Amended Schedule
13E-3
                                                            Filed August 5,
2022
                                                            File No. 005-90857
                                                            color:white;"_
                                                            Revised Preliminary
Proxy Statement on Schedule 14A
                                                            Filed August 5,
2022
                                                            File No. 001-38794

       Dear Ms. Fenster:

              We have reviewed your amended filings and have the following
comments. In some of
       our comments, we may ask you to provide us with information so we may
better understand your
       disclosure.

               Please respond to these comments by providing the requested
information or advise us as
       soon as possible when you will respond. If you do not believe our
comments apply to your facts
       and circumstances, please tell us why in your response.

              After reviewing your response to these comments, we may have
additional
       comments. All defined terms used here have the same meaning as in your
revised preliminary
       proxy statement.

       Amended Schedule 13E-3 filed August 5, 2022

       Exhibits

   1.                                                   We note you will
request confidential treatment for certain portions of these exhibits.
                                                        Please refile the
exhibit index and exhibits that are subject to the confidential treatment
                                                        request to include the
requisite legend. Please note that, once received, we will conduct
                                                        our review of your
request separately.
 Amanda Fenster
FirstName LastNameAmanda
Weil, Gotshal & Manges LLP Fenster
Comapany
August 10, NameWeil,
           2022       Gotshal & Manges LLP
August
Page 2 10, 2022 Page 2
FirstName LastName
2.       We note your response to comment 2. Your response indicates that
"Deutsche Bank
         Securities Inc. (   Deutsche Bank   ), UBS Investment Bank (   UBS
), BMO Capital Markets
         and Mizuho Securities USA LLC served as financial advisors to the CD&R
Entities in
         connection with the transaction." We further note your representation
that those entities
         did not provide any reports within the meaning of Item 1015 of
Regulation M-A. Note
         that "reports" for these purposes include oral presentations or
engagements with filing
         parties where information materially related to the going private
transaction is provided.
         Please confirm that no such oral reports were provided and explain
what these three
         entities did as financial advisors. To the extent that reports are
summarized in the revised
         proxy statement as a result of this comment, please additionally
provide the information
         required by Item 1015(a) of Regulation M-A as to the three financial
advisors, as well as a
         summary of the reports pursuant to Item 1015(b).
Revised Preliminary Proxy Statement on Schedule 14A filed August 5, 2022

Reasons for the Merger; Recommendation of the Board; Fairness of the Merger,
page 32

3.       We note your response to comment 7 indicating that the Board and
Transaction
         Committee did not base their fairness determination on Goldman Sachs'
fairness opinion.
         However, the disclosure on page 34 of the revised proxy statement
states that the
         Transaction Committee and the Board "considered the oral opinion of
Goldman Sachs,
         subsequently confirmed by delivery of its written opinion" in reaching
a determination
         that the Merger is fair and recommending its approval to shareholders.
Please revise to
         adopt the underlying analysis and conclusions as previously requested,
or delete the
         references to the Goldman Sachs opinion in this section.
Alternatively, revise the proxy
         statement disclosure to specifically state that the Goldman Sachs
fairness opinion was not
         relied upon by the Board and Transaction Committee in assessing the
fairness of this
         going private transaction.
General

4.       We note your response to comment 13. We do not necessarily agree with
your analysis or
         conclusion but have no further comment at this time.
        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
 Amanda Fenster
Weil, Gotshal & Manges LLP
August 10, 2022
Page 3

      Please direct any questions to Michael Killoy at 202-551-7576 or
Christina Chalk at 202-
551-3263.



FirstName LastNameAmanda Fenster                          Sincerely,
Comapany NameWeil, Gotshal & Manges LLP
                                                          Division of
Corporation Finance
August 10, 2022 Page 3                                    Office of Mergers &
Acquisitions
FirstName LastName